Clinical Trial Update: A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of PF-06801591 in multiple solid tumors including melanoma, head and neck cancer, ovarian cancer, sarcoma, non-small cell lung c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Sarcoma
• Urothelial Carcinoma

Drugs mentioned

• PF-06801591 (PF-06801591)

Snippet

Sponsor: Pfizer | Conditions: Part 1, MELANOMA | Phase 1 | Status: COMPLETED | Results posted: 2021-12-13